🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — November 2025 Page 9

SOUL trial preliminary data — November 2025

JenMemphis Sun, Mar 16, 2025 at 2:50 AM 51 replies 2,130 viewsPage 9 of 11
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
Apr 6, 2025 at 12:51 PM#41
Dr.KarenChen said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

16 14MaxMetOK, MounjBrad, nick_newbie and 13 others
Reply Quote Save Share Report
wei_SG
Member
234
890
Nov 2024
Singapore, SG
Apr 7, 2025 at 8:17 AM#42
Dr.KarenChen said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

Adding the part of the answer the thread has not reached. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Last edited: Apr 7, 2025 at 9:17 AM
17 15SaraMom3, Dr.MetabolicMD, RetaRick_CA and 14 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Apr 8, 2025 at 3:43 AM#43

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.

18 16RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 15 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Apr 8, 2025 at 11:08 PM#44

Following on from Dr.KarenChen — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

19 17PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 16 others
Reply Quote Save Share Report
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Apr 9, 2025 at 6:33 PM#45
wei_SG said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

This is where I part company with the consensus forming above. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.

20 18PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 17 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register